A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine

@article{Fleishaker2004APA,
  title={A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine},
  author={J. Fleishaker and L. K. Hulst},
  journal={European Journal of Clinical Pharmacology},
  year={2004},
  volume={46},
  pages={35-39}
}
We have assesed the pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzodiazepine.Healthy men took fluvoxamine maleate daily for 10 days (50 mg on days 1–3, 100 mg on days 4–10) (n=20), 1 mg of alprazolam four times daily for four days (days 7–10 of the study period) (n=20), or a combination of the two (n=20), according to a parallel study design. Alprazolam and fluvoxamine concentrations were measured in serial… Expand
Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone
TLDR
Results suggest that caution with the use of midazolam is warranted with potent CYP3A4 inhibitors, and pharmacodynamic data are consistent with pharmacokinetic data indicating that nefazodone and ketoconazole resulted in significant increases in midzolam‐related cognition impairment. Expand
The Influence of Fluvoxamine Administration on Glibenclamide Pharmacokinetics After Multiple Oral Dosing in Rats
TLDR
Results indicated that following the single dose administration, glibenclamide C„, was 415±1 69ng/ml, T„„ was 3.7±1.4h, t, and fluvoxamine, a potent inhibitor of cytochrome P450 (CYP) isoenzymes may be coadministered with glibanclamide. Expand
Fluvoxamine Affects Sildenafil Kinetics and Dynamics
TLDR
Whereas the pharmacokinetic changes do not suggest a large clinically relevant interaction, it may be prudent to consider a starting dose of 25 mg in patients concurrently treated with fluvoxamine. Expand
Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles
TLDR
Coadministration of FLV significantly increased the plasma concentrations of ALP compared with ALP monotherapy, and wide variations were observed in the drug interactions, with the CYP2C19 genotype possibly being related to these interactions. Expand
Effects of Concomitant Fluvoxamine on the Plasma Concentration of Etizolam in Japanese Psychiatric Patients: Wide Interindividual Variation in the Drug Interaction
TLDR
Wide variations were observed in the drug interactions; however, coadministration with fluvoxamine produced significant changes in the plasma concentrations of etizolam (P < 0.0001). Expand
Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy Volunteers
TLDR
Study results showed no evidence for pharmacologic interactions between paroxetine and alprazolam at steady state, and Psychomotor Performance Tests and Visual Analogue Scales data suggested lack of pharmacodynamic interactions. Expand
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
TLDR
A potent inhibitory effect of fluvoxamine on CYP2C19 activity is confirmed and the bioavailability of omeprazole might, to some extent, be increased through inhibition of P-glycoprotein during fluv oxamine treatment. Expand
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia
TLDR
It is indicated that fluvoxamine increases plasma haloperidol concentrations in a dose-dependent manner, however, relatively small elevations in hal operidol concentration did not lead to the development of extrapyramidal symptoms under the conditions of this study. Expand
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
TLDR
Aripiprazole can be used safely in combination with SSRIs that have a CYP enzyme-inhibitory action, and no apparent differences were found between two CYP2D6 genotypes in fluvoxamine coadministration. Expand
In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine.
TLDR
Results indicated fluvoxamine has a modest inhibitory effect on the activity of CYP2C19, but no effect on that of CyP2D6 in vivo. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects
TLDR
The relationships between alprazolam and metabolite concentrations and CNS effects were determined in a double-blind placebo controlled four-way crossover trial in 16 normal male volunteers, suggesting a tolerance which was sustained during the 10-day washout between phases. Expand
Clinical Pharmacokinetics of Alprazolam
TLDR
Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 μg/L, which may be needed for suppression of the actual panic attacks. Expand
Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.
TLDR
Steady-state pharmacokinetic values during the multiple-dose phase correlated with values observed following the single dose, and alprazolam elimination was more rapid in smokers than in nonsmokers. Expand
Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
TLDR
With the exception of rapidity of onset, the pharmacodynamic profiles of IV and oral alprazolam are very similar after a 1.0-mg dose and kinetic parameters are not affected by route of administration. Expand
Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men.
TLDR
Although not significantly different, alprazolam elimination was more rapid in smokers than in nonsmokers and Steady-state pharmacokinetic values during the multiple-dose phase correlated with values observed following the single dose. Expand
Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects
TLDR
The results suggest that it is not necessary to adjust the dosage of fluvoxamine in elderly depressed patients, on the basis of pharma-cokinetic arguments. Expand
Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
TLDR
Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients. Expand
Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
TLDR
In patients with depressive illness, fluvoxamine offers a suitable alternative to tricyclic antidepressants and may be especially valuable in patients with concomitant cardiovascular disease, and those unresponsive to or unable to tolerate tricyClic antidepressants. Expand
Clinical Pharmacokinetics of Selective Serotonin Reuptake Inhibitors
TLDR
Although many attempts were made, to date no convincing evidence exists of a relationship between plasma concentrations of any of the SSRIs and clinical efficacy, and available data indicate that metabolism ofSSRIs is impaired with reduced liver function. Expand
Determination of clovoxamine concentration in human plasma by electron capture gas chromatography.
TLDR
When this assay was applied to plasma from individuals involved in an early clinical trial of clovoxamine, steady-state plasma concentrations ranged from 50 to 77 micrograms/L 3 h after a 50-mg oral dose of clvoxamine fumarate. Expand
...
1
2
...